Cargando...
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
BACKGROUND: The phase ½ hemophilia B clinical trial (AMT-060) demonstrated stable endogenous FIX levels after 3.5 years (mean FIX activity between 5.1% and 7.5%) with continued reductions in annualized bleeds to near zero with the higher dose, and a 78–96% reduction by year in exogenous FIX use. OBJ...
Guardado en:
| Publicado en: | Patient Prefer Adherence |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7184858/ https://ncbi.nlm.nih.gov/pubmed/32368018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S239810 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|